SCHEMBL3015352

SCHEMBL3015352

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c1C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
ALDH1A1 P00352 4/20 0.43
ALDH3A1 P30838 1/20 0.43
TP53 P04637 2/20 0.42
TDP1 Q9NUW8 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 3/20 0.40
POLB P06746 2/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
SMPD1 P17405 1/20 0.39
KDM2B Q8NHM5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018408 0.93 TRPV4 (0.43) MAPTALDH1A1TP53TSHRSMN1; SMN2
SCHEMBL3004102 0.93 MAPT (0.44) MAPTALDH1A1ALDH3A1TP53TDP1
SCHEMBL3009041 0.91 TP53 (0.44) MAPTALDH1A1TP53L3MBTL1SMN1; SMN2
SCHEMBL3018789 0.91 MEN1 (0.45) MAPTALDH1A1TP53TDP1L3MBTL1
SCHEMBL3002429 0.91 MAPT (0.44) MAPTALDH1A1ALDH3A1TP53TDP1
SCHEMBL3019130 0.90 ALDH1A1 (0.49) MAPTALDH1A1TP53TSHRL3MBTL1
SCHEMBL3011195 0.90 MEN1 (0.45) MAPTALDH1A1TP53TSHRL3MBTL1
SCHEMBL3016087 0.89 LMNA (0.47) MAPTALDH1A1TP53TDP1TSHR
SCHEMBL3013472 0.88 SMN1; SMN2 (0.38) MAPTALDH1A1ALDH3A1TSHRSMN1; SMN2
SCHEMBL3021348 0.88 MAPT (0.42) MAPTALDH1A1TP53TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885ALDH3A1 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.